Recipharm
Recipharm gains EU Hub's approval to submit serialisation data
Contract development and manufacturing organisation (CDMO) Recipharm has received approval by the European Medicines Verification Organisation (EMVO) to submit serialisation data to the European Hub. more
Meeting compliance: Challenges for CDMOs before the EU FMD deadline
In this interview, we at EPM magazine speak with Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the European Falsified Medicines Directive (EU FMD) deadline in February 2019. more
Post-Brexit strategy vote — pharma industry opinions
Last week, the UK government saw heated debates and closely contested votes on the post-Brexit strategy, including a favourable outcome for the future relationship of the UK and the European Medicines Agency (EMA) more
Less than six months until EMA relocates: What are some of the thoughts from industry?
Now we have just passed the six-month marker (1 July) until the European Medicines Agency (EMA) moves from its current location in London to Amsterdam, as a result of Brexit, we gauge industry response to this change… more
Recipharm acquires Sanofi’s Holmes Chapel manufacturing centre and business
CDMO, Recipharm, has acquired Sanofi’s manufacturing centre and business located in Holmes Chapel, which will provide the company with a platform to take advantage of the growing respiratory drug market. more
Recipharm partners with Hadasit, supporting regional growth
Contract development and manufacturing organisation (CDMO), Recipharm, has partnered with Hadasit Medical Research Services and Development to deliver combined clinical, biological and chemical services. more
CMO Leadership Awards recognise Recipharm as winner in six categories
Contract development and manufacturing organisation (CDMO), Recipharm, has been recognised in the CMO Leadership Awards for 2018, organised by Life Science Leader. more
Recipharm reveals winner of 2017 International Environmental Award
Contract development and manufacturing organisation (CDMO), Recipharm, has revealed that the winner of its 2017 International Environmental Award is Karen Kidd more
Licensing agreement formed for co-development of new value added medicines
Contract development and manufacturing organisation (CDMO), Recipharm, has signed a licensing agreement with Canadian drug development company, Altus Formulation, to offer new drug delivery technologies for value added medicines. more
The final countdown is on for EU FMD compliance: What are the experts saying?
Today (Friday 9 Feburary 2018) marks the precise point that we are a year away until the European Union Falsified Medicines Directive (EU FMD) comes into force. Here, we feature some expert opinions more
Recipharm acquires remaining shares in Indian company
Recipharm has taken a step further in its development and growth in the Indian market by acquiring the remaining shares in Nitin Lifesciences. more
Sector highlights: Recipharm interview
Mark Quick, executive vice president of corporate development, Recipharm, goes into detail about the opportunities his company has faced this year as well as the challenges. more
Inflection point: Reviewing the industry opportunities, challenges and trends of 2017
With the industry experiencing dramatic change, from regulatory changes to investments in capacity and the uncertainty of the political landscape, we asked several industry heads to review the opportunities, challenges and trends of 2017. more
Recipharm recognised for its commitment to its operations in France
CDMO, Recipharm, has been awarded with ‘le Prix d’Excellence 2017 — Spécial Sciences de la vie’ by the Swedish Chamber of Commerce in France in recognition of its commitment to its French operations more
Pharma cannot afford to relax on DSCSA, experts say
Today (Monday 27 November) marks the original deadline date for the DSCSA. While the FDA has delayed its enforcement of compliance with these serialisation requirements by a year, pharma is still required to legally comply. Industry tells us more… more
The top five tweets: From Merck to BioLive — what did EPM readers rate this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
Take your pick: Revealing the benefits of high-throughput screening
Traditionally, excipient selection has been performed using trial-and-error based methodologies, which are time-consuming and expensive. In this article, Dr Amjad Alhalaweh, PhD, formulation scientist, Recipharm, discusses a new method, HTS more
Table talk — industry leaders reveal what they think are the current ‘mega trends’
In this roundtable, four industry leaders from Symbiosis Pharmaceutical Services, Recipharm, Sterling Pharma Solutions and Idifarma, reveal their thoughts on what the ‘mega trends’ are in the current pharma landscape. more
Floor fillers, day 1 — the latest from CPhI WW’s show floor
Here, we reveal some of the news, developments and product innovations that have been released from the show floor of day 1 of this year’s CPhI Worldwide congress in Frankfurt more
Collaboration formed to develop and manufacture KAND567
Contract development and manufacturing organisation (CDMO) — Recipharm and Kancera, a development company focused on cancer therapy, have entered into a contract for the development and manufacture of the pharmaceutical candidate KAND567. more
